{
    "Trade/Device Name(s)": [
        "Access Vitamin B12",
        "Access Vitamin B12 Assay"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K223289",
    "Predicate Device Reference 510(k) Number(s)": [
        "K955436"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CDD"
    ],
    "Summary Letter Date": "December 23, 2022",
    "Summary Letter Received Date": "October 25, 2022",
    "Submission Date": "October 25, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1810"
    ],
    "Regulation Name(s)": [
        "Vitamin B12 test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Vitamin B12"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (heparin)"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "Access Immunoassay Systems",
        "DxI 9000 Access Immunoassay Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic particle immunoassay",
        "Automated",
        "Competitive binding immunoenzymatic assay"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access Vitamin B12 assay for quantitative determination of vitamin B12 levels in serum and plasma using immunoassay analyzers",
    "Indications for Use Summary": "Quantitative determination of vitamin B12 levels in human serum and plasma (heparin) to aid in diagnosis and treatment of anemias of gastrointestinal malabsorption",
    "fda_folder": "Clinical Chemistry"
}